Medigene AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGEF research report →
Companywww.medigene.com
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies.
- CEO
- Ralph Schafer
- IPO
- 2013
- Employees
- 87
- HQ
- Munich, DE
Price Chart
Valuation
- Market Cap
- $38.17M
- P/E
- -0.10
- P/S
- 0.33
- P/B
- 0.08
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 72.77%
- Op Margin
- -267.63%
- Net Margin
- -268.10%
- ROE
- -55.69%
- ROIC
- -61.86%
Growth & Income
- Revenue
- $6.03M · -80.69%
- Net Income
- $-16,177,000 · -94.20%
- EPS
- $-1.32 · -106.25%
- Op Income
- $-16,149,000
- FCF YoY
- -243.89%
Performance & Tape
- 52W High
- $2.59
- 52W Low
- $0.10
- 50D MA
- $2.59
- 200D MA
- $2.59
- Beta
- 1.36
- Avg Volume
- 5.36K
Get TickerSpark's AI analysis on MDGEF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MDGEF Coverage
We haven't published any research on MDGEF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MDGEF Report →